[HTML][HTML] Cysteine cathepsins: A long and winding road towards clinics
M Biasizzo, U Javoršek, E Vidak, M Zarić… - Molecular Aspects of …, 2022 - Elsevier
Biomedical research often focuses on properties that differentiate between diseased and
healthy tissue; one of the current focuses is elevated expression and altered localisation of …
healthy tissue; one of the current focuses is elevated expression and altered localisation of …
Preclinical development in radiopharmaceutical therapy for prostate cancer
Prostate cancer is a leading cause of cancer death in men worldwide. Among the various
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …
Radiolabeled bombesin analogs
R Mansi, BA Nock, SU Dalm, MB Busstra… - Cancers, 2021 - mdpi.com
Simple Summary Recent medical advancements have strived for a personalized medicine
approach to patients, aimed at optimizing therapy outcomes with minimum toxicity. In this …
approach to patients, aimed at optimizing therapy outcomes with minimum toxicity. In this …
Radiopharmaceuticals targeting gastrin-releasing peptide receptor for diagnosis and therapy of prostate cancer
Y Zou, M Huang, M Hu, H Wang, W Chen… - Molecular …, 2024 - ACS Publications
The high incidence and heavy disease burden of prostate cancer (PC) require accurate and
comprehensive assessment for appropriate disease management. Prostate-specific …
comprehensive assessment for appropriate disease management. Prostate-specific …
[99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
BA Nock, A Kaloudi, P Kanellopoulos, B Janota… - Cancers, 2021 - mdpi.com
Simple Summary Radiolabeled gastrin-releasing peptide receptor (GRPR)-antagonists have
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …
Synthesis and Evaluation of a Cathepsin B–Recognizing Trifunctional Chelating Agent to Improve Tumor Retention of Radioimmunoconjugates
H **da, K Nakashima, H Watanabe… - Journal of Labelled …, 2024 - Wiley Online Library
Cathepsin B (CTSB) is a lysosomal protease that is overexpressed in tumor cells.
Radioimmunoconjugates (RICs) composed of CTSB‐recognizing chelating agents are …
Radioimmunoconjugates (RICs) composed of CTSB‐recognizing chelating agents are …
Genetic and pharmacological inhibition of GRPR protects against acute kidney injury via attenuating renal inflammation and necroptosis
C Li, Q Ma, X Liu, M Yu, S ** inhibitor in an antagonistic NTSR1-targeted construct for colon cancer
Many low-molecular weight targeted radiotherapeutics (TRTs) are capable of rapidly
achieving exceptional tumor to non-target ratios shortly after administration. However, the …
achieving exceptional tumor to non-target ratios shortly after administration. However, the …
Examination of the impact molecular charge has on NTSR1-targeted agents incorporated with cysteine protease inhibitors
Our laboratory has previously reported a strategy of employing cysteine cathepsin (CC)
inhibitors as adduct forming, trap** agents to extend the tumor residence time of …
inhibitors as adduct forming, trap** agents to extend the tumor residence time of …
Status and future directions of anti-metastatic cancer nanomedicines for the inhibition of cathepsin L
Angiogenesis, tissue invasion and metastasis in the tumour microenvironment are all critical
hallmarks of cancer. Upregulation of cathepsin L plays an important role in angiogenesis …
hallmarks of cancer. Upregulation of cathepsin L plays an important role in angiogenesis …